We are live on ! Find out more
NMC

NEA Management Company Portfolio holdings

AUM $1.76B
1-Year Est. Return 223.33%
This Fund
S&P 500
This Quarter Est. Return
+40.41%
1 Year Est. Return
+223.33%
3 Year Est. Return
+769.45%
5 Year Est. Return
+668.45%
10 Year Est. Return
+14,843.34%
AUM
$1.96B
AUM Growth
+$139M
Cap. Flow
-$121M
Cap. Flow %
-6.15%
Top 10 Hldgs %
86.5%
Holding
30
New
1
Increased
3
Reduced
–
Closed
3

Top Buys

Rank Stock Value
1
CELC icon
Celcuity
CELC
+$114M
2
ZBIO
Zenas BioPharma
ZBIO
+$26M
3
XFOR icon
X4 Pharmaceuticals
XFOR
+$3.63M
4
LONA
LeonaBio Inc
LONA
+$2.13M

Top Sells

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$240M
2
NEUE
NeueHealth
NEUE
+$18.2M
3
OMDA
Omada Health Inc
OMDA
+$8.05M

Sector Composition

Rank Sector Weight
1 Healthcare 95.17%
2 Consumer Staples 4.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELC icon
1
Celcuity
CELC
$4.42B
$353M 17.98%
3,535,561
+1,391,300
+65% +$114M
RYTM icon
2
Rhythm Pharmaceuticals
RYTM
$7.23B
$311M 15.88%
2,909,956
– –
ACLX
3
DELISTED
Arcellx
ACLX
$199M 10.12%
3,045,262
– –
TRVI icon
4
Trevi Therapeutics
TRVI
$2.49B
$166M 8.44%
13,222,228
– –
SVRA icon
5
Savara
SVRA
$1.12B
$148M 7.52%
24,471,264
– –
ZBIO
6
Zenas BioPharma
ZBIO
$1.96B
$128M 6.52%
3,523,219
+789,500
+29% +$26M
GLUE icon
7
Monte Rosa Therapeutics
GLUE
$2.02B
$121M 6.15%
7,692,298
– –
MBX
8
MBX Biosciences
MBX
$2.88B
$114M 5.81%
3,614,486
– –
COUR icon
9
Coursera
COUR
$1.57B
$94.7M 4.83%
12,867,769
– –
AUPH icon
10
Aurinia Pharmaceuticals
AUPH
$1.98B
$63.3M 3.23%
3,969,834
– –
GOSS icon
11
Gossamer Bio
GOSS
$73M
$56.1M 2.86%
18,093,034
– –
CRSP icon
12
CRISPR Therapeutics
CRSP
$4.7B
$55.5M 2.83%
1,058,570
– –
ORIC icon
13
Oric Pharmaceuticals
ORIC
$1.11B
$33.7M 1.72%
4,118,621
– –
PHAT icon
14
Phathom Pharmaceuticals
PHAT
$855M
$32.5M 1.66%
1,960,169
– –
CVRX icon
15
CVRx
CVRX
$128M
$14.4M 0.73%
2,026,083
– –
XFOR icon
16
X4 Pharmaceuticals
XFOR
$341M
$12.9M 0.66%
3,233,743
+1,000,000
+45% +$3.63M
CSBR icon
17
Champions Oncology
CSBR
$85.1M
$11.8M 0.6%
1,713,720
– –
BDTX icon
18
Black Diamond Therapeutics
BDTX
$103M
$10.8M 0.55%
4,448,757
– –
KRRO icon
19
Korro Bio
KRRO
$163M
$8.74M 0.45%
1,090,793
– –
IVA
20
Inventiva
IVA
$1.06B
$6.8M 0.35%
1,462,586
– –
NKTX icon
21
Nkarta
NKTX
$186M
$6.6M 0.34%
3,568,781
– –
SNTI icon
22
Senti Biosciences Holdings
SNTI
$13.5M
$3.93M 0.2%
3,775,615
– –
LONA
23
LeonaBio Inc
LONA
$72M
$3.52M 0.18%
+464,398
New +$2.13M
SYBX
24
DELISTED
Synlogic
SYBX
$3.27M 0.17%
2,922,772
– –
MRKR icon
25
Marker Therapeutics
MRKR
$21.8M
$2.42M 0.12%
1,625,678
– –
1
2

Similar funds

NM
NWI Management New York $1.76B AUM 45.08% 1-Year Est. Return
EK
Evensky & Katz Coral Gables, Florida $1.76B AUM 18.21% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.76B AUM 19.57% 1-Year Est. Return
PCA
Prosperity Capital Advisors Westlake, Ohio $1.76B AUM 18.92% 1-Year Est. Return
CCIA
Campbell & Co Investment Adviser Baltimore, Maryland $1.76B AUM 13.06% 1-Year Est. Return
SRIM
Saratoga Research & Investment Management Saratoga, California $1.76B AUM 15.32% 1-Year Est. Return
SW
Simplicity Wealth Summit, New Jersey $1.76B AUM 20.49% 1-Year Est. Return
CGH
Contrarius Group Holdings Hamilton, Bermuda $1.77B AUM 83.15% 1-Year Est. Return

NEA Management Company's Q4 2025 Portfolio in Review

As of Q4 2025, NEA Management Company held 30 positions worth $1.96B, up 7.6% from $1.82B the previous quarter. Its ten largest holdings account for 86% of the portfolio.

NEA Management Company withdrew a net $121M in Q4 2025, closing 3 positions. Its most notable exit was Verona Pharma, an estimated $240M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 92% a quarter earlier, followed by Consumer Staples.

Against the trend, NEA Management Company opened a new position in LeonaBio Inc worth $3.52M.

  • NEA Management Company's largest Q4 2025 buy was LeonaBio Inc: 464,398 shares worth $3.52M.
  • NEA Management Company added most to Celcuity in Q4 2025, an estimated $114M increase.
  • NEA Management Company fully exited Verona Pharma in Q4 2025, selling an estimated $240M.
  • NEA Management Company's ten largest holdings make up 86% of its $1.96B portfolio in Q4 2025.
  • NEA Management Company opened 1 new position and closed 3 in Q4 2025.
  • NEA Management Company's portfolio value rose 7.6% quarter-over-quarter to $1.96B.

Based on NEA Management Company's 13F filing for Q4 2025, filed 17 Feb 2026.